⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535764 | 1.00 | — | — | |
| SCHEMBL1751707 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL7710591 | 0.97 | — | — | |
| Ethylene Glycol SCHEMBL1171278 | 0.93 | FOLH1 (0.50) | — | |
| SCHEMBL1171215 | 0.91 | FOLH1 (0.48) | — | |
| SCHEMBL1171034 | 0.91 | FOLH1 (0.48) | — | |
| Propylene Glycol SCHEMBL3087494 | 0.89 | FOLH1 (0.46) | — | |
| 1,4-Butanediol SCHEMBL6003713 | 0.89 | GPR84 (0.50) | — | |
| SCHEMBL6004016 | 0.87 | GPR84 (0.54) | — | |
| SCHEMBL3082579 | 0.87 | FOLH1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3851126-A1 | MAYTANSINOID-CELL-BINDING AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3524611-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3524611-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-3031810-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-1651162-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150071949-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8841425-B2 | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| CN-101186613-B | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN INC | 2014-09-17 | — | — | CN | disclosed |
| US-8435528-B2 | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7851432-B2 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7473796-B2 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070269447-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7276497-B2 | For therapy of tumors | IMMUNOGEN INC. | 2007-10-02 | — | — | US | disclosed |
| US-20040235840-A1 | For therapy of tumors | IMMUNOGEN, INC. | 2004-11-25 | — | — | US | disclosed |